AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18402657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized normative feedback intervention
Number of subjects: 0
Study 18402657 — intervention group
Group type: COMPARATOR
Intervention: Control group (measurement effects)
Number of subjects: 0
Study 18402657 — intervention group
Group type: COMPARATOR
Intervention: Control group (intervention effects)
Number of subjects: 0
Study 15837357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol (50mg/kg/day in four divided doses for 14 days)
Number of subjects: 50
Study 15837357 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (15 mg/kg/day in two divided doses for 3 days)
Number of subjects: 50
Study 12028688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 76
Study 12028688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (750 mg)
Number of subjects: 76
Study 12028688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 76
Study 12028688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 10477984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 200
Study 10477984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Bond
Number of subjects: 200
Study 10477984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 8708763 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion lung scans with 1-3 small subsegmental defects
Number of subjects: 0
Study 8708763 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion lung scans with > 3 small subsegmental defects
Number of subjects: 0
Study 1918724 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1.2 mg per day
Number of subjects: 40
Study 1918724 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2.4 mg per day
Number of subjects: 40
Study 1918724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1918724 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing schedule
Number of subjects: 40
Study 6578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum samples collected from the 1st to 26th postinfarction days
Number of subjects: 9
Study 6578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cytologic features observed
Number of subjects: 9
Study 6578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to canine model
Number of subjects: 9
Study 6578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Case presentation
Number of subjects: 9
Study 31916540 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified CBD (Epidiolex/Epidyolex; >99% CBD)
Number of subjects: 0
Study 31302043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4735
Study 31302043 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4735
Study 28653328 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling pressure of 40 mm Hg (group 1)
Number of subjects: 240
Study 28653328 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling pressure of 60 mm Hg (group 2)
Number of subjects: 240
Study 28653328 — intervention group
Group type: COMPARATOR
Intervention: Filling pressure of 80 mm Hg (group 3; control)
Number of subjects: 240
Study 27094610 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (FG-4592)
Number of subjects: 145
Study 25458329 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 34
Study 25458329 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 34
Study 25458329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 34
Study 22093134 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGV) 900 mg b.i.d. for 7 days followed by 900 mg daily for up to 21 days
Number of subjects: 37
Study 22093134 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir (GCV) 5 mg/kg b.i.d. for 7 days followed by daily GCV 5 mg/kg for up to 21 days
Number of subjects: 37
Study 19233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear microphonic potential (CM) recorded by extratympanic electrocochleography
Number of subjects: 0
Study 19233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion-product otoacoustic emissions (OAEs)
Number of subjects: 0
Study 19233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear microphonic potential (CM)
Number of subjects: 0
Study 19233252 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion-product OAEs and CM monitored in gerbils during intracranial pressure changes
Number of subjects: 0
Study 17466917 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (in vitro sensitivity measurement)
Number of subjects: 74
Study 17466917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodamine 123 (Rh123) extrusion measurement
Number of subjects: 74
Study 17466917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (in vitro resistance measurement)
Number of subjects: 74
Study 17466917 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 gene polymorphisms assessment
Number of subjects: 74
Study 15089791 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Treatment and Teaching Programme (STTP) combining dietary freedom with insulin adjustment
Number of subjects: 0
Study 15089791 — intervention group
Group type: COMPARATOR
Intervention: Current standard practice for treatment of Type 1 diabetes
Number of subjects: 0
Study 12547241 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose complex therapy
Number of subjects: 0
Study 12547241 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron administration
Number of subjects: 0
Study 12547241 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters (ferritin, transferrin saturation)
Number of subjects: 0
Study 12547241 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein level
Number of subjects: 0
Study 9440474 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 microg/kg)
Number of subjects: 9
Study 9440474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9440474 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I
Number of subjects: 9
Study 9440474 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I and Placebo
Number of subjects: 9
Study 7662901 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NAME (NO synthase inhibitor) at doses of 40 micrograms kg‐1 injected plus 50 micrograms kg‐1 infused i.v.
Number of subjects: 7
Study 7662901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 7
Study 7662901 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg
Number of subjects: 7
Study 7662901 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) 200 micrograms i.v.
Number of subjects: 7
Study 3385105 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with household measures
Number of subjects: 0
Study 3385105 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with food models
Number of subjects: 0
Study 3385105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trained groups
Number of subjects: 0
Study 3385105 — intervention group
Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 0
Study 30270800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 250 mg intravenously
Number of subjects: 120
Study 30270800 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study 25401685 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge condition (vignette that challenges belief in a just world)
Number of subjects: 1041
Study 25401685 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (vignettes that confirm or do not attempt to influence belief in a just world)
Number of subjects: 1041
Study 23261785 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of reaching
Number of subjects: 0
Study 16527227 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5%
Number of subjects: 62
Study 16527227 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1%
Number of subjects: 62
Study 16527227 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 62
Study 16527227 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (ketorolac, indomethacin, artificial tears)
Number of subjects: 62
Study 12617689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) (<0.1 W/cm(2))
Number of subjects: 0
Study 10371400 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.0 g/kg (Control)
Number of subjects: 18
Study 10371400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 18
Study 10371400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg
Number of subjects: 18
Study 8660070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction therapy with additional intensification treatment (two blocks of intensification)
Number of subjects: 1612
Study 8660070 — intervention group
Group type: COMPARATOR
Intervention: No intensification treatment
Number of subjects: 1612
Study 8660070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction therapy
Number of subjects: 1612
Study 8660070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification treatment
Number of subjects: 1612
Study 8660070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT)
Number of subjects: 1612
Study 8660070 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Down's syndrome
Number of subjects: 1612
Study 1997060 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol as an anaesthetic induction agent
Number of subjects: 13
Study 1997060 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (21 subjects)
Number of subjects: 13
Study 6337412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 22
Study 6337412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 22
Study 6337412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg
Number of subjects: 22
Study 6337412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 22
Study 30670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medicine (CAM) use
Number of subjects: 153
Study 30670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of social support
Number of subjects: 153
Study 30670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower health literacy skills
Number of subjects: 153
Study 30670282 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy relating to engaging with health care providers
Number of subjects: 153
Study 30670282 — intervention group
Group type: COMPARATOR
Intervention: Decision-making self-efficacy
Number of subjects: 153
Study 27881395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight-loss group (calorie-restricted diet for 6 weeks)
Number of subjects: 54
Study 27881395 — intervention group
Group type: COMPARATOR
Intervention: No-weight loss control group (maintained habitual diet and physical activity levels)
Number of subjects: 54
Study 25792086 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally
Number of subjects: 75
Study 25792086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22781136 — intervention group
Group type: EXPERIMENTAL
Intervention: PR plus SSRT
Number of subjects: 19
Study 22781136 — intervention group
Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 19
Study 20628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 11140
Study 20628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 11140
Study 20628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 11140
Study 20628304 — intervention group
Group type: COMPARATOR
Intervention: Receiver Operating Characteristic Curve
Number of subjects: 11140
Study 20628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Integrated Discrimination Improvement Statistic
Number of subjects: 11140
Study 19076960 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing the screen
Number of subjects: 157
Study 19076960 — intervention group
Group type: COMPARATOR
Intervention: Not seeing the screen
Number of subjects: 157
Study 17509259 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scanning
Number of subjects: 0
Study 17509259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical recommendations for PET scans
Number of subjects: 0
Study 14702590 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional materials (labels)
Number of subjects: 10
Study 14702590 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional materials (labels plus signs)
Number of subjects: 10
Study 14702590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no promotional materials)
Number of subjects: 10
Study 11464149 — intervention group
Group type: EXPERIMENTAL
Intervention: Stated willingness to participate (WTP)
Number of subjects: 610
Study 11464149 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of basic vaccine trial concepts
Number of subjects: 610
Study 9336506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam and Vancomycin
Number of subjects: 0
Study 9336506 — intervention group
Group type: COMPARATOR
Intervention: Imipenem and Cilastatin
Number of subjects: 0
Study 9336506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid analysis
Number of subjects: 0
Study 8178250 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 132
Study 3228990 — intervention group
Group type: COMPARATOR
Intervention: 5% cocaine
Number of subjects: 0
Study 3228990 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla (lignocaine and prilocaine mixture)
Number of subjects: 0
Study 29606370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led group discussions
Number of subjects: 170
Study 29606370 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 170
Study 28971609 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0
Study 28971609 — intervention group
Group type: COMPARATOR
Intervention: Three tested coffees
Number of subjects: 0
Study 28971609 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 26643109 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviprostat (two capsules, q 8 h) for 8 weeks
Number of subjects: 100
Study 26643109 — intervention group
Group type: COMPARATOR
Intervention: Pollen extract (Cernilton) (two capsules, q 8 h) for 8 weeks
Number of subjects: 100
Study 26643109 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviprostat
Number of subjects: 100
Study 26643109 — intervention group
Group type: COMPARATOR
Intervention: Pollen extract
Number of subjects: 100
Study 26643109 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviprostat and Pollen extract
Number of subjects: 100
Study 24250291 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training program (work: rest ratio of 1:1, 8 weeks, 45-60 minutes, 60-79% of HR max)
Number of subjects: 245
Study 24250291 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary during the 8 weeks)
Number of subjects: 245
Study 20848374 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured discharge planning intervention
Number of subjects: 241
Study 18440315 — intervention group
Group type: COMPARATOR
Intervention: Continuation of immunosuppressives (Con)
Number of subjects: 80
Study 18440315 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of immunosuppressives (Dis)
Number of subjects: 80
Study 16531926 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐FP‐CIT SPECT imaging in Parkinson's disease
Number of subjects: 56
Study 16531926 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐FP‐CIT SPECT imaging in PSP
Number of subjects: 56
Study 16531926 — intervention group
Group type: COMPARATOR
Intervention: Comparison of I‐FP‐CIT SPECT imaging between Parkinson's disease and PSP
Number of subjects: 56
Study 16531926 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric index (AI) in Parkinson's disease
Number of subjects: 56
Study 14629883 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy (group 2)
Number of subjects: 32
Study 14629883 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (group 1)
Number of subjects: 32
Study 10907942 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day tamoxifen
Number of subjects: 494
Study 10907942 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 494
Study 9195356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 42
Study 9195356 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 42
Study 1356922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol beer (alcohol restriction)
Number of subjects: 86
Study 1356922 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake reduction (4,200-6,300 kJ/day)
Number of subjects: 86
Study 1356922 — intervention group
Group type: COMPARATOR
Intervention: Normal alcohol intake (control)
Number of subjects: 86
Study 1356922 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 86
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (single dose)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (single dose)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg (single dose)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (chronic administration for 7 days)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg (chronic administration for 7 days)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg (chronic administration for 7 days)
Number of subjects: 0
Study 2865148 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol (multisubject comparison)
Number of subjects: 0
Study 31228861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion system (CIIS)
Number of subjects: 48
Study 31228861 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin administrations (MDI)
Number of subjects: 48
Study 31228861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CIIS and MDI
Number of subjects: 48
Study 29727385 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6g thrice daily
Number of subjects: 150
Study 29727385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29727385 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA)
Number of subjects: 150
Study 26649938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prolonged magnesium sulfate infusion (50 mg/kg/hr for 4 hours)
Number of subjects: 38
Study 26649938 — intervention group
Group type: COMPARATOR
Intervention: Bolus magnesium sulfate (50 mg/kg over 1 hour)
Number of subjects: 38
Study 26649938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prolonged magnesium sulfate infusion
Number of subjects: 38
Study 26649938 — intervention group
Group type: COMPARATOR
Intervention: Bolus magnesium sulfate
Number of subjects: 38
Study 24506775 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution 0.2% administered three times a day for 1 day
Number of subjects: 0
Study 24506775 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.07% applied twice daily for 29 days
Number of subjects: 0
Study 24506775 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.18% applied once daily for 29 days
Number of subjects: 0
Study 24506775 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.18% applied twice daily for 29 days
Number of subjects: 0
Study 24506775 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel 0.5% applied once daily for 29 days
Number of subjects: 0
Study 22686073 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (10 mg/d) in the Western medicine group (WM)
Number of subjects: 60
Study 22686073 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine treatment by syndrome typing in the Chinese medicine group (CM)
Number of subjects: 60
Study 22686073 — intervention group
Group type: COMPARATOR
Intervention: Combination of Benazepril and Chinese herbs in the combination group
Number of subjects: 60
Study 20511580 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone booster intervention (weekly reinforcement of clinic advice)
Number of subjects: 46
Study 20511580 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 17606976 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT)
Number of subjects: 650
Study 17606976 — intervention group
Group type: COMPARATOR
Intervention: Extended-field radiotherapy (EF-RT) alone
Number of subjects: 650
Study 17606976 — intervention group
Group type: COMPARATOR
Intervention: Treatment of relapse after EF-RT
Number of subjects: 650
Study 17606976 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of second malignancies
Number of subjects: 650
Study 16267763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate with abacavir/lamivudine
Number of subjects: 340
Study 16267763 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz with abacavir/lamivudine
Number of subjects: 340
Study 12131112 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR 15 group (15 microg x kg(‐1) x min(‐1) amrinone with a 1.0‐mg/kg loading dose)
Number of subjects: 30